We have previously reported tumour-selective killing by the sigma (r) receptor ligand rimcazole. We now report that rimcazole elevates hypoxia inducible factor-1a (HIF-1a) protein levels under normoxic conditions in colorectal (HCT-116) and mammary carcinoma (MDA MB 231) cells but fails to induce HIF-1a in normal fibroblasts or mammary epithelial cells. Combining the r-1 agonist ( þ )-pentazocine with rimcazole substantially reduces the accumulation of HIF-1a, confirming that the effect is mediated at least partly by antagonism of r-1 sites. HIF-1a knockdown by RNA interference attenuates rimcazoleinduced cell death in both cell types. Thus, the induction of HIF-1a by rimcazole contributes to tumour cell killing. In a comparison of HCT-116p53 +/+ and HCT-116p53 cells. This suggests that the presence of functional p53 protein may enhance death induction by rimcazole in part through greater induction of HIF-1a. p53 is not required, however, for the rimcazole-induced engagement of HIF-1a in proapoptotic mode as HIF-1a knockdown attenuates rimcazole-induced death to comparable extents in p53 mutant and wild-type cell systems. Knowledge of HIF-1a involvement may assist the re-profiling of rimcazole and other r ligands as cancer therapeutics.
Introduction
Organisms that use aerobic respiration need to maintain oxygen levels within tight boundaries. Excess oxygen (hyperoxia) can lead to cellular damage via production of reactive oxygen species, and lack of oxygen (hypoxia) causes depletion in ATP, thereby compromising cellular metabolism (Semenza, 1999; Semenza, 2001) . Cancer development involves sequential mutation in oncogenes and tumour suppressor genes that give a selective growth advantage to the evolving cancer cell and colorectal cancer progression is one of the most well characterized (Arends, 2000) . Cancers that outstrip their blood supply become hypoxic and need to adapt through genetic change or alterations in signalling pathways in order to grow in such conditions.
The microenvironment of the cancer cell helps to drive mutational change and also places pressure on the signalling pathways that control the checkpoint responses. Stressors that play a role in tissue transformation include genotoxic DNA-damaging agents, pro-oxidants, lowered oxygen concentration, low extracellular pH and thermal injury (Graeber et al., 1996; Nitta et al., 1997; Giaccia and Kastan, 1998; Williams et al., 1999) . Adaptation to such stresses is implicated in the evolution of solid tumour growth where acidification, oxygen limitation and glucose starvation place limitations on cell growth.
Mutation of p53 is thought to be a key event leading to enhanced growth in lowered oxygen concentrations. Anoxia rather than hypoxia has been reported to drive the acquisition by tumours of inactivating p53 mutations (Magnusson et al., 1998) . Consistent with this, the p53 pathway has been shown to respond differentially to greater or lesser degrees of oxygen deprivation, helping the tumour to adapt or succumb. A recent in vitro study revealed that hypoxia silences the p53 transactivation response, whereas anoxia or severe hypoxia can activate p53 (Achison and Hupp, 2003) .
One of the key transducers of the hypoxic response is the transcription factor hypoxia-inducible factor-1a (HIF-1a). Steady-state levels of HIF-1a protein are modulated by an oxygen-responsive signalling pathway that controls VHL-dependent degradation of HIF-1a and also by growth factor signalling in normoxic conditions. HIF-1a protein is constitutively degraded by the VHL tumour suppressor gene under normal oxygen concentrations, but can be stabilized by lowered oxygen concentrations or by agents that chelate iron, thereby mimicking anoxic conditions. HIF-1a induction is also mediated by IGF-1 in cells grown under normal oxygen concentrations, thus uncoupling HIF-1a induction from oxygen deprivation (Fukuda et al., 2002; Yim et al., 2003) .
HIF-1a is reported to induce gene products implicated in a host of cellular responses, including angiogenesis, proliferation, survival and glucose metabolism, leading to cell survival under limiting oxygen concentrations. On the other hand, HIF-1a has also been shown to act in a proapoptotic and antitumorigenic manner in some circumstances (Bacon and Harris, 2004) . HIF-1a protein induction in hypoxic or anoxic cells has also been reported to be variously p53-dependent, p53-independent, and ATR-dependent (Chun and Jin, 2003; Hammond et al., 2003) . Two studies have revealed direct interactions between HIF-1a and p53, suggesting that the two proteins could form a specific complex in cells (Hansson et al., 2002; Fels and Koumenis, 2005) . However, any impact that the association between HIF-1a and p53 might have on the apoptotic response is at present unclear.
We have previously reported in vitro and in vivo antitumour activity of small-molecule s ligands including the s receptor antagonist rimcazole (Spruce et al., 2004) . Here we describe the selective accumulation of HIF-1a protein in response to rimcazole, mediated through s-1 sites, in human tumour cells but not normal dermal fibroblasts or mammary epithelial cells. Rimcazole induces HIF-1a in a proapoptotic mode, as abrogation of the HIF-1a response by RNA interference (RNAi) attenuates rimcazole-induced death in both hormone-insensitive mammary carcinoma and colorectal carcinoma cells. This suggests that the induction of HIF-1a by rimcazole assists the apoptotic and antitumour response to the drug. To investigate the possible role of p53 in the rimcazole-induced accumulation of HIF-1a protein, we compared isogenic HCT-116 cells that differ only in their p53 status. The accumulation of HIF-1a following rimcazole treatment is more pronounced in cells with wild-type p53 and induction of death by rimcazole is consistently greater in HCT-116 p53-positive cells. On the other hand, HIF-1a RNAi attenuates rimcazole-induced cell killing in the presence and absence of functional p53 protein in colorectal cancer cells and in the absence of functional p53 protein in mammary carcinoma cells. Thus, while p53 may enhance the rimcazole antitumour response, in part, through engagement of the HIF-1a pathway, p53 is not required to reveal the proapoptotic function of HIF-1a in response to rimcazole.
Results
HIF-1a protein accumulates transiently in colorectal cancer cells destined to die in response to rimcazole Given that the HIF-1a pathway can be a modulator of antitumour outcome in both hypoxic and normoxic conditions, it was relevant to investigate whether antitumour effects mediated through the sigma (s) receptor, and in response to rimcazole in particular, involve the HIF-1a pathway. We treated colorectal cancer cells þ / þ ) in culture with rimcazole and noted a transient accumulation of HIF-1a protein, maximal at 6 h, in response to rimcazole (Figure 1a ). There was no change in p53 protein levels in response to rimcazole over the same time period (Figure 1a ). HIF-1a protein levels returned to normal steady-state levels within 24 h (Figure 1a) . In cell viability (MTS) assays conducted in parallel, rimcazole caused a concentrationdependent decline in viable cell number relative to control cell populations (Figure 1b) . The transient accumulation of HIF-1a in cells that later died in response to rimcazole suggested participation of the HIF-1a pathway in the decision of cells to die in response to rimcazole.
HIF-1a accumulates selectively in cancer cells but not in normal human dermal fibroblasts or normal human mammary epithelial cells To investigate whether the accumulation of HIF-1a might be a general response of tumour cells that are susceptible to rimcazole, we investigated other cancer cell lines, including hormone-insensitive mammary carcinoma cells (MDA MB 231); thus far, all cancer cell lines tested exhibit HIF-1a accumulation in response to rimcazole, to varying degrees. In HCT-116p53
and MDA MB 231 cells HIF-1a accumulated in a dosedependent manner, suggesting that the level of HIF-1a accumulation might contribute to a signal that determines the amount of death induction or growth inhibition (Figure 2a and b) . In contrast, normal human þ / þ colorectal cancer cells. Cells were exposed to Rim (50 mM) (Tocris Cookson Ltd (1497), Avonmouth, UK) for times shown and then HIF-1a and p53 protein levels were examined by immunoblotting using anti-HIF-1a (1:1000 dilution) (BD Transduction Laboratories, Cat. No. 610958) and anti-p53 (DO-1, 1:1000) monoclonal antibodies (a). þ / þ colorectal cancer cells were treated with Rim at the concentrations shown for up to 48 h before having cell viability analysed using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (MTS) (Promega, G3581 (Spruce et al, 2004) , show no accumulation of HIF-1a (Figure 2c ). In addition, non-transformed mammary epithelial cells at low passage show no accumulation of HIF-1a ( Figure 2d ) and are resistant to killing by rimcazole (Spruce et al., 2004) . Together, these data suggest that a rise in cellular HIF-1a protein levels correlates with susceptibility to rimcazole.
Agonistic signalling at s-1 sites opposes HIF-1a accumulation in response to rimcazole and the anoxia mimetic DFX We have previously shown that the antitumour effects of rimcazole are mediated at least, in part, by antagonism of s-1 sites (Spruce et al., 2004) . However, as rimcazole is known to bind with high affinity to the dopamine transporter, it was of interest to determine whether the accumulation of HIF-1a was mediated specifically through the s-1 receptor. We therefore investigated whether application of rimcazole in the presence of a highly specific s-1 agonist, ( þ )-pentazocine, would modulate HIF-1a accumulation. When HCT-116p53
þ / þ cells were pre-treated with ( þ )-pentazocine, even at subequivalent concentrations, there was a substantial reduction in the level of HIF-1a after rimcazole treatment ( Figure 3a ). This implies that the elevation in HIF-1a protein in response to rimcazole is mediated at least, in part, by specific antagonism at s-1 sites. Interestingly, pre-treatment with higher concentrations of ( þ )-pentazocine substantially attenuated the HIF-1a response to the anoxia mimetic deferoxamine mesylate (DFX) (Figure 3b ). This suggests that signalling through the s-1 receptor opposes HIF-1a accumulation in response to anoxia. Rim-induced HIF-1a accumulates selectively in cancer cells but not in normal human dermal fibroblasts or normal human mammary epithelial cells HCT-116p53 þ / þ cells were treated with Rim at the concentrations shown for 4 h and then HIF-1a protein levels were examined by immunoblotting using anti-HIF-1a (1:1000 dilution) (BD Transduction Laboratories, Cat. No. 610958) antibodies (a). MDA MB 231 cells were treated with Rim at the concentrations shown for 4 h and then HIF-1a protein levels were examined by immunoblotting using anti-HIF-1a antibodies as above (b). Normal human dermal fibroblasts were treated with Rim at the concentrations shown for 4 h and then HIF-1a protein levels were examined by immunoblotting using anti-HIF-1a antibodies (c). Normal human mammary epithelial cells were treated with Rim at the concentrations shown for 4 h and then HIF-1a protein levels were examined by immunoblotting using anti-HIF-1a antibodies (d). Cell lysates were immunoblotted using anti-Actin antibodies (mAbcam 8226-200) at 1:1500 dilution as a loading control. 
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Accumulation of HIF-1a in response to rimcazole is partly p53 dependent The relationship between the p53 pathway and HIF-1a protein induction is complex. In an attempt to determine the possible contribution of the p53 pathway to the rimcazole-induced HIF-1a response, we compared isogenic strains of HCT-116 cells that differ only in p53
) (Bunz et al., 1999) . We have previously shown in isogenic HCT-116 cells that the accumulation of HIF-1a in hypoxic and anoxic cells is independent of p53 status (Achison and Hupp, 2003) . However, detectable elevation of HIF-1a by rimcazole occurred at lower drug concentrations in HCT-116p53
À/À cells ( Figure 4a ). Furthermore, the onset of HIF-1a elevation occurred more rapidly in þ / þ cells compared to HCT-116p53 À/À cells ( Figure 4b ). Therefore, unlike the response of HIF-1a to lowered oxygen concentration that is p53-independent, the elevation of HIF-1a in response to rimcazole appears to be enhanced in the presence of functional p53 protein.
p53 assists the apoptotic response to rimcazole in HCT-116 cells To investigate whether the enhancement of HIF-1a protein accumulation in the presence of p53 might influence the apoptotic response to rimcazole, we compared the response of HCT-116p53
HCT-116p53
À/À cells exposed to rimcazole in cell viability (MTS) assays (Figure 5a(i) ) and by flow cytometric quantification of apoptotic cells (cells with subnormal DNA content, sub-G0 cells; Figure 5a (ii)). After 48 h of continuous exposure to rimcazole at 10 and 20 mM or to drug vehicle alone, there were 40-50% fewer viable cells in rimcazole-treated cells compared to untreated þ / þ cells (Figure 5a (i), right hand bars). In contrast, viable cell numbers were unaffected by 48 h of rimcazole treatment at concentrations of 10 and 20 mM in HCT-116p53 À/À cells (Figure 5a (i), left hand bars). To investigate whether the enhanced cytotoxicity in the presence of p53 protein may be owing to apoptosis induction, we conducted flow cytometric analysis of propidium iodide-stained cells, after exposure to 50 mM rimcazole for different time intervals, to determine the percentage of cells with subnormal DNA content (sub-G0, that is, apoptotic cells) (Figure 5a (ii)). Although there was a modest increase in apoptotic (sub-G0) cell numbers after 24 h continuous exposure to rimcazole in HCT-116p53 À/À cells, there was a substantially greater number of sub-G0 cells in the HCT116p53
population. The differential effect of rimcazole on HCT-116 cells, relative to the presence or absence of p53 protein, was confirmed by Trypan blue uptake, which assays late-stage apoptotic and necrotic cells. In the Trypan blue assay, there was more cell death in þ / þ cells compared to HCT116p53 À/À cells when treated with 50 mM rimcazole (Figure 5b ). Furthermore, on phase microscopy ( Figure  5c i-iv), cells were more evidently rounded and detached after exposure to rimcazole in the HCT-116p53 þ / þ cell population, consistent with engagement of an apoptotic programme. Therefore, although p53 is not required for rimcazole to induce cell death in HCT-116 cells, cell death is enhanced, as measured in a number of ways, in the presence of p53 protein.
Rimcazole kills tumour cells in part via an HIF-1a-mediated proapoptotic programme We had observed that HIF-1a accumulates more rapidly, and after exposure to lower concentrations of rimcazole, in þ / þ cells compared to HCT116p53 À/À cells ( Figure 4a and b) ; furthermore, that rimcazole induces a greater percentage increase in apoptotic cell numbers in the presence of p53 ( Figure  5a (ii)). Together, these data suggested that rimcazole may be activating the HIF-1a pathway in a proapoptotic mode. To investigate this, we employed RNAi to knockdown HIF-1a using a set of pooled, short interfering RNAs, following which, cells were exposed to rimcazole or drug vehicle. Cell viability (MTS) assays were conducted on HCT-116p53 þ / þ cells after exposure to rimcazole for periods up to 48 h, in the presence of HIF-1a RNAi, or a control, non-targeting RNAi. There was an almost twofold greater number of viable cells remaining after 48 h treatment with rimcazole at 10 and 20 mM concentrations in the presence of HIF-1a RNAi, compared with cells treated with rimcazole in the presence of control RNAi (Figure 6a ). At higher implying that at least in this cell system, rimcazole may be inducing HIF-1a to act in a proapoptotic mode.
Given that p53 appears to enhance apoptosis in response to rimcazole in HCT-116 cells, it was of interest þ / þ and HCT116p53 À/À cells were treated with Rim (50 mM) for the times shown. Cells were harvested and the cell cycle parameters were analysed by flow cytometry, as described previously (Achison and Hupp, 2003) , and expressed as the sub-G0 phase. Graphs depict representative experiments performed at least three times (a(ii)). þ / þ and HCT-116p53 À/À cells were treated with Rim (50 mM) for the times shown; cell death (late stage apoptotic and/or necrotic) was assessed microscopically by uptake of Trypan blue (0.4% Trypan blue solution, Sigma, Cat. No. T-8154, mixed 1:1 with tissue culture medium) (b). Phase micrographs of HCT-116p53 þ / þ and HCT-116p53 À/À cells before and after treatment with Rim (50 mM) for 60 min (c). Rimcazole kills cells, in part, via an HIF-1a-mediated proapoptotic programme HCT-116p53 þ / þ cells were transfected with HIF-1a RNAi or control, non-targeting RNAi and then treated with rimcazole at 10 or 20 mM or untreated as control in 96-well plates. Cells were then assessed for viability using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay. MTS assay points represent mean values (7s.d.) obtained from 96-well plates in triplicate, expressed relative to control (pretreatment) values. Graphs depict representative experiments performed at least three times. The legend depicts the type of RNAi used (control or HIF-1a) (a). MDA MB 231 cells were transfected with HIF-1a RNAi or control RNAi, and then treated with either rimcazole at 10 or 20 mM or drug vehicle in 96-well plates. Cells were then assessed for viability as above. The legend depicts the type of RNAi used (control or HIF-1a) and the concentration of rimcazole used (10 or 20 mM) (b). Confirmation of HIF-1a knockdown by HIF-1a RNAi was demonstrated by immunoblotting cell lysates using anti-HIF-1a antibodies following treatment of cells with rimcazole, DFX or drug vehicle. Cont ¼ cells transfected with control RNAi; HIF ¼ cells transfected with HIF-1a RNAi; Rim ¼ rimcazole used at 20 mM for 4 h and DFX ¼ DFX used at 100 mM for 4 h (c).
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M Achison et al may be programmed to function in a proapoptotic mode even without rimcazole stimulation. To investigate whether this property of HIF-1a extended to other tumour cell types in which p53 function was absent, we studied the MDA MB 231 cell line, a mammary carcinoma cell line that possesses mutant p53. MDA MB 231 cells were exposed to rimcazole or drug vehicle alone, after treatment with either HIF-1a RNAi or control RNAi (Figure 6b ). Satisfactory knockdown of HIF-1a was confirmed by immunoblotting (Figure 6c ). In the MDA MB 231 cell line, HIF-1a RNAi on its own conferred an increase in viable cell number compared to control RNAi, suggesting that HIF-1a has a negative effect on cell viability and/or proliferation in these cells.
In the presence of rimcazole, the protection conferred by HIF-1a RNAi was also pronounced, implying that rimcazole has the capacity to enhance the proapoptotic activity of HIF-1a above a basal level (Figure 6b ). Together, these data indicate that rimcazole causes an accumulation of HIF-1a protein that assists the apoptotic response and that this proapoptotic mode of HIF-1a activation does not require the presence of functional p53 protein.
Discussion
We have previously shown that rimcazole induces tumour cell-selective killing, in part, through caspasedependent apoptosis (Spruce et al., 2004) , but spares a range of normal cells. In this paper, we describe the cellselective accumulation of HIF-1a protein in colorectal and mammary carcinoma cell lines, cell lines that die in response to rimcazole. In contrast, normal human dermal fibroblasts and non-transformed human mammary epithelial cells, which remain viable in the presence of concentrations of rimcazole that are lethal to tumour cells, show no such accumulation of HIF-1a. This suggests that a rise in HIF-1a levels may be either a marker of, or a contributor to, the tumour-selective killing effect of rimcazole. HIF is known to act in both antiapoptotic (protumorigenic) and proapoptotic (tumour suppressor) capacities. For example, in renal cell carcinoma, the HIF-1a and HIF-2a isoforms have been described as having opposing effects on tumour growth, with HIF-1a retarding and HIF-2a enhancing tumour growth. Furthermore, HIF-1a causes induction of the proapoptotic gene product BNip3 (Bcl2/adenovirus EIB 19 kDainteracting protein 3) in renal carcinoma cells (Raval et al., 2005) . There have been several other reports that suggest involvement of HIF-1a in the initiation of apoptosis by causing an increase in proapoptotic proteins including RTP801, which is dependent on cell oxidative conditions (Shoshani et al., 2002) and Noxa, a p53 gene target implicated in p53-dependent apoptosis, whose promoter responds to an increase in hypoxia via HIF-1a (Kim et al., 2004) . Alternatively, hypoxic induction of HIF-1a can cause an increase in antiapoptotic proteins such as inhibitor of apoptosis (IAP)-2 and a decrease in proapoptotic proteins such as Bax (Greijer and van der Wall, 2004) . This suggests that the HIF-1a pathway can encourage either death or survival outcomes in lowered oxygen environments. One reason for this dichotomy may be to encourage HIF-1a to act in a way that promotes cellular adaptation and survival in moderately lowered oxygen concentrations; however, under more severe oxygen deprivation, orderly selfdestruction of terminally injured cells through engagement of HIF-1a in an apoptotic mode would be logical.
Under normoxic conditions, an accumulation of HIF-1a through enhanced gene expression or posttranscriptional mechanisms has also been reported. For example, growth factor signalling through IGF-1 induces HIF-1a gene expression via mitogen activated protein kinase and PI-3 kinase-dependent pathways in HCT-116 colorectal carcinoma cells in the absence of hypoxia (Fukuda et al., 2002) . Furthermore, HER2 neu signalling in breast cancer cells stimulates HIF-1a protein synthesis via PI-3 kinase and mTOR-dependent pathways (Laughner et al., 2001) . Cytokines including tumour necrosis factor (TNF)-a have also been shown to cause HIF-1a protein accumulation through a post-transcriptional mechanism that is dependent on the activation of a nuclear factor-kB-dependent pathway (Zhou et al., 2003) . It is not clear from available data whether normoxic induction of HIF-1a solely drives an antiapoptotic outcome or whether a proapoptotic fate is also possible. However, given that different biochemical pathways can cause the accumulation of HIF-1a under normoxic and hypoxic conditions, it is tempting to speculate that upregulated growth factor-and/or cytokine-dependent signalling could allow the two pathways to cooperate to maximize tumour survival in low oxygen tension.
Our study has revealed a tumour-selective increase in HIF-1a protein levels in normoxic cells treated with the s receptor antagonist rimcazole. Given that rimcazole has been taken previously to clinical trials for a different indication, and therefore has a known safety profile in man, it presents a relatively low-risk opportunity to test its potential as a cancer therapeutic. It is important therefore to know whether the accumulation of HIF-1a represents acquisition of a potential antiapoptotic, resistance pathway, or whether the elevation in HIF-1a is encouraging the apoptotic, and therefore antitumour, response. In both p53-null and p53 wild-type cell systems, depletion of HIF-1a using RNAi consistently revealed an attenuation of the cell death response to rimcazole, strongly implying that the induction of HIF-1a is favouring an apoptotic outcome. This would be consistent with the reports referred above in which HIF-1a is suggested to have a proapoptotic function.
Whether the accumulation of HIF-1a protein in response to rimcazole is due to an increase in HIF-1a gene expression or a reduction in VHL-mediated degradation of HIF-1a cannot be determined on the basis of the data so far. Hypoxia causes a rise in HIF-1a levels through inactivation of the VHL E3 ligase, which prevents proteasome-mediated degradation of VHL and its partner HIF-1a. Whether rimcazole is mediating HIF-1a elevation through an interference with HIF-1a degradation or through an increase in HIF-1a gene expression, or possibly through both, could have implications for the response of hypoxic vs normoxic tumours to rimcazole and for tumours driven by growth factor pathways.
We confirmed that the HIF-1a response to rimcazole is mediated at least in part through s-1 sites by competition experiments using a highly specific s-1 agonist, ( þ )-pentazocine. Although rimcazole itself is a non-selective s ligand that also binds the dopamine transporter (Gilmore et al., 2004) , highly specific small molecule s-1 agonists do exist. In s-1 knockout mice, binding of brain membranes to the s-1 agonist ( þ )-pentazocine is abolished, providing evidence that ( þ )-pentazocine acts solely through s-1 sites (Langa et al., 2003) . The attenuation of rimcazole-induced HIF-1a accumulation by ( þ )-pentazocine confirms that the effect is mediated, in part, through s-1 sites. The effect of ( þ )-pentazocine in reducing HIF-1a accumulation in response to DFX also suggests that agonistic signalling through s-1 receptors opposes anoxia-mediated activation of the HIF-1a pathway. We have previously shown that the s-1 receptor confers an antiapoptotic function in transformed cell lines (Spruce et al., 2004) . It is possible therefore that stimulatory signalling through the s-1 receptor may suppress induction of HIF-1a in a proapoptotic mode.
There is increasing evidence for a functional link between p53, which controls the cellular damage response, and HIF-1a, which mediates cellular adaptation to low oxygen concentrations. However, the relationship between the two pathways appears complex, cooperation and antagonism having both been reported (Chen et al., 2003) . It has been shown that p53 protein mediates apoptosis in response to low oxygen concentrations with concomitant activation of HIF-1a presumptively in survival mode (Graeber et al., 1996) . According to this model, the induction of HIF-1a would allow the cellular adaptation to low oxygen concentrations and favour the evolution of clones with mutant p53 that resist the apoptotic signal. Other studies have shown differences in the nature of the p53 response according to the level of oxygen deprivation. Mild hypoxia has been reported to induce p53-dependent gene repression via histone deacetylase interactions, whereas severe hypoxia activates the classic p53-dependent transcription programme (Koumenis et al., 2001) . We have shown previously that hypoxia attenuates the p53 response to cellular damage by silencing a p53 transactivation pathway, whereas chemically mimicked anoxia activates p53 transactivation; furthermore, hypoxia inhibits genotoxin-induced, p53-dependent cell death (Achison and Hupp, 2003) . Another study has shown that anoxia rather than hypoxia may be a driving force for the evolution of cell populations with mutations in p53 (Magnusson et al., 1998) . Together, these data suggest that the presence of p53 does not oppose and may even encourage survival under mild hypoxic conditions; however, in anoxia, p53 is encouraged to mediate a proapoptotic outcome and therefore must be selected against if a tumour is to survive under severe oxygen deprivation. p53 appears to encourage the apoptotic response to rimcazole in one cell system (HCT-116 colorectal cancer cells). The greater induction of apoptosis in response to rimcazole in HCT-116 cells that possess wild-type p53 may be due, in part, to accumulation of HIF-1a more rapidly and to higher levels in the presence of p53. One possibility was that rimcazole-induced HIF-1a accumulation could lead to stabilization of p53 protein and thence to enhanced apoptosis induction, as stabilization of p53 by HIF-1a has been reported previously . However, we have shown no increase in p53 protein levels in response to rimcazole. Other more recent work has suggested binding of HIF-1a to p53 via the unstructured oxygen-dependent degradation domain of HIF-1a to the p53 core domain under physiological conditions (Sanchez-Puig et al., 2005) . One possible explanation therefore for the greater accumulation of HIF-1a in response to rimcazole in the presence of p53 is that binding of p53 to HIF-1a helps to protect HIF-1a from degradation.
Molecular interactions between p53 and HIF-1a that are both direct (Hansson et al., 2002; Sanchez-Puig et al., 2005) and indirect via Mdm2 (Chen et al., 2003) have been reported. On the other hand, competition between HIF-1a and p53 for the shared transcriptional co-activator p300 has also been described (Schmid et al., 2004) . Thus, p53 and HIF-1a appear to have the capacity to physically interact directly and indirectly, or to exclude each other from interaction with a binding partner, p300. This would suggest the potential for cooperation or antagonism between the HIF-1a and p53 pathways; thus, the greater induction of HIF-1a in the presence of p53 does not necessarily imply that this will enhance apoptosis in response to rimcazole. On the other hand, our demonstration that rimcazole-induced apoptosis is attenuated when HIF-1a is knocked down in the presence of p53 would support a model whereby the two are cooperating to promote an apoptotic outcome. Thus far, we have only determined that p53 influences the apoptotic response to rimcazole in one cell system, whether it does so in other tumour cell systems remains to be established. Certainly, p53 is required neither for the apoptotic nor antitumour responses to rimcazole both in vitro and in vitro (Spruce et al., 2004) , but there could be potential for further modulation through the p53 pathway.
Tumour-selective killing by the s receptor ligand rimcazole, in part via HIF-1a, may open up a new approach to cancer treatment. The ability to kill cancer cells while leaving healthy cells unaffected was surprising given the ubiquity of s receptor expression in normal as well as tumour tissue. The capacity of the s receptor antagonist rimcazole to derepress selectively a 'proapoptotic arm' of the HIF-1a pathway in tumour but not normal cells suggests that HIF-1a may contribute to an Achilles' heel through which tumour but not normal cells succumb to rimcazole. The relevance of these findings to the potential for hypoxic tumours, or to normoxic tumours that have acquired an HIF-1a-mediated resistance pathway, to respond to rimcazole remains to be investigated.
Materials and methods
Cell culture HCT-116 human colorectal carcinoma cell lines (p53-wild-type and functional p53-null containing a deletion of the p53 transactivation domain) were a kind gift from Dr Bert Vogelstein (Waldman et al., 1995; Bunz et al., 1999) (Johns Hopkins University, Baltimore, MD, USA) and maintained as a monolayer culture in McCoys 5A modified medium (GibcoBRL, 26600-023) supplemented with 10% foetal bovine serum (GibcoBRL, 10099-141) and 1% penicillin (10 000 IU/ ml)-streptomycin (10 000 mg/ml) (GibcoBRL, 15140114) Sample preparation DFX was resuspended in ddH 2 O and added at the indicated concentrations. Cultures were then removed at the times stated and immediately had medium removed, washed using ice-cold phosphate-buffered saline (PBS), trypsinized using trypsin-ethylenediaminetetraacetic acid (GibcoBRL, 25300-054) for 1 min at 371C and all components combined in a 50 ml plastic tube held on ice. Cells were then centrifuged at 1000 r.p.m. for 4 min in an MSE Mistral 1000 centrifuge followed by two washes using 10 ml ice-cold PBS, before resuspension in 1.0 ml ice-cold PBS. Each sample was then split with 0.4 ml reserved for florescence-activated cell sorter (FACS) analysis and 0.6 ml used for Western analysis. FACS analysis samples were fixed by the addition of 4.0 ml 70% ice-cold ethanol with vigorous mixing and held at 41C for up to 1 week.
Western analysis
Western analysis samples were centrifuged at 13 000 r.p.m. for 1 min at room temperature using an Eppendorf S417R centrifuge and pellets resuspended in 100 ml urea lysis buffer (8 M urea, 1% Triton, 100 mM dithiothreitol (DTT), 50 mM HEPES, pH 7.6), held on ice for 20 min, and then centrifuged at 13 000 r.p.m. at 41C for 20 min. The use of urea as a core component of the lysis buffer prevents the dephosphorylation of p53 during lysis. Supernatant fluid was then retained for protein analysis using the Bradford method. Equal amounts of protein (20-50 mg) were added to an equal volume of Laemmli sample buffer (5% SDS, 25% glycerol, 125 mM Tris, few grains bromophenol blue, 1 mM DTT, pH 8.0) and then subjected to electrophoresis using an Invitrogen Novex mini-cell system with NuPage pre-cast 4-12% gradient gels (NP0323). Following transfer to nitrocellulose, samples were then subjected to protein immunoblotting.
FACS analysis
Each sample fixed in 70% ethanol was centrifuged at 1000 r.p.m. for 5 min at room temperature and pellet resuspended in 1.0 ml PBS. Cells were counted using a Neubauer haemocytometer and adjusted to 7.5 Â 10 5 cells/ml in PBS. RNAse A (100 ml of 1 mg/ml) (Sigma Aldrich, Poole, Dorset, England) and propidium iodide (100 ml of 400 mg/ml) (Sigma) were added to 1.0 ml of cells in an FACS tube (Falcon) and incubated at 371C for 30 min. Samples (10 000 cells) were then immediately analysed using Cellquest software on a Beckton Dickinson FACScan flow cytometer.
RNAi assay SiGENOME SMARTpool reagent Human HIF-1a (M-004018-02-0010) was supplied by Dharmacon and used according to the manufacturer's instructions and based on work by others (Krishnamachary et al., 2003) . Specifically, HIF-1a RNAi was dissolved in 1 Â stock buffer to give a 20 mM solution. This was then combined with Optimem reduced serum medium (Gibco, 31985-047) and Lipofectamine 2000 (Invitrogen Ltd, Paisley, Scotland, UK, 11668-027), and added to cells (1 Â 10 5 /ml) at a final concentration of 100 nM. Transfected cells were then transferred into 96-well plates in 100 ml aliquots and left overnight in 371C incubator. Nontargeting RNAi was prepared in the same way and used as a control. Cells were then subjected to different concentrations of rimcazole and analysed using the CellTiter 96 AQ ueous One Solution Cell Proliferation Assay (Promega, G3581).
Cell viability/proliferation assay
The MTS CellTitre 96 AQ ueous One Solution Cell Proliferation Assay (Promega, G3581) was used to determine cell viability in control and drug-treated cell populations. This colorimetric assay is dependent on the conversion of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulphonyl)-2H-tetrazolium (MTS) compound to a coloured, soluble formazan product in metabolically active cells. Cells were seeded in 96-well microtitre plates at a density of 1 Â 10 5 À2 Â 10 5 cells/ml serum-containing (10% FCS) culture medium and left to adhere for B18 h. Cells were then exposed to s ligands at a range of concentrations in 10% FCScontaining medium for the duration of the experiment. Cell viability was measured before drug addition and at intervals postdrug addition up to 72 h. The absorbance at 490 nm was read in a Dynex microtiter plate reader (Thermo Labsystems, Ashford, UK). Cell viability is represented as the ratio of absorbance at time ' Â ' (post-drug addition) minus drugged blank readings (medium with drug but without cells) over absorbance at time 0 (before drug addition) minus blank readings (medium without drugs or cells), expressed as a percentage. One-hundred per cent reflects viable cell numbers at the start of the experiment; values >100% represent net cell proliferation, and values o100% indicate net cell loss (cytotoxicity and not merely cell detachment because the assay measures viable, non-adherent as well as adherent cells).
